In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases

In situ-based gel drug delivery systems that can bypass the blood-brain barrier, deliver the therapeutics to the desired site, reduce peripheral toxicity and control drug release kinetics have been developed. Some of the therapeutics used to treat neurological diseases suffer from poor bioavailabili...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 10; no. 2; p. 40
Main Author Aderibigbe, Blessing Atim
Format Journal Article
LanguageEnglish
Published Switzerland MDPI 30.03.2018
MDPI AG
Subjects
Alzheimer’s disease
brain tumor
drug delivery systems
in situ-based gels
neurological diseases
nose-to-brain delivery
Review
drug delivery systems
neurological diseases
brain tumor
Alzheimer’s disease
in situ-based gels
nose-to-brain delivery
Online AccessGet full text

Cover

More Information
Summary:In situ-based gel drug delivery systems that can bypass the blood-brain barrier, deliver the therapeutics to the desired site, reduce peripheral toxicity and control drug release kinetics have been developed. Some of the therapeutics used to treat neurological diseases suffer from poor bioavailability. Preclinical reports from several researchers have proven that the delivery of drugs to the brain via the nose-to-brain route using in situ gels holds great promise. However, safety issues on the toxicity of the nasal mucosa, transportation of the drugs to specific brain regions and determination of the required dose are factors that must be considered when designing these gels. This review will be focused on in situ-based gels that are used for the delivery of therapeutics via the nose-to-brain route, preclinical reports and challenges.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics10020040